{"protocolSection":{"identificationModule":{"nctId":"NCT06137300","orgStudyIdInfo":{"id":"TK-LAA"},"organization":{"fullName":"The First Hospital of Jilin University","class":"OTHER"},"briefTitle":"Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke","officialTitle":"Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke：a Multicentre, Prospective, Randomised, Open-label, Blinded-Endpoint Trial"},"statusModule":{"statusVerifiedDate":"2023-11","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-12-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-06-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-11-14","studyFirstSubmitQcDate":"2023-11-14","studyFirstPostDateStruct":{"date":"2023-11-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-11-14","lastUpdatePostDateStruct":{"date":"2023-11-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Yi Yang","investigatorTitle":"Associated Dean of the First Hospital of Jilin University","investigatorAffiliation":"The First Hospital of Jilin University"},"leadSponsor":{"name":"Yi Yang","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety and efficacy of urinary kallidinogenase treatment in patients with large artery atherosclerotic acute ischemic stroke.","detailedDescription":"Currently, evidence regarding the safety and efficacy of urinary kallidinogenase treatment in patients with acute ischemic stroke lacks, and few of related studies were large-scale and high-quality. Thus, this study was designed to evaluate the safety and efficacy of urinary kallidinogenase treatment in patients with large artery atherosclerotic acute ischemic stroke."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["Acute Ischemic Stroke, Urinary Kallidinogenase"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":986,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Urinary Kallidinogenase group","type":"EXPERIMENTAL","description":"Patients are treated with urinary kallidinogenase and guideline-prescribed basic medical therapy.","interventionNames":["Drug: Urinary kallidinogenase for injection"]},{"label":"Control group","type":"OTHER","description":"Patients are only treated with guideline-prescribed basic medical therapy.","interventionNames":["Other: Guideline-prescribed medical therapy"]}],"interventions":[{"type":"DRUG","name":"Urinary kallidinogenase for injection","description":"Urinary kallidinogenase 0.15PNA once daily for 7 days.","armGroupLabels":["Urinary Kallidinogenase group"],"otherNames":["Guideline-prescribed medical therapy"]},{"type":"OTHER","name":"Guideline-prescribed medical therapy","description":"Guideline-prescribed medical therapy","armGroupLabels":["Control group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Proportion of patients with Modified Rankin Scale (mRS) Score 0-2 at 90 days","description":"Modified Rankin Scale (mRS) ranged from 0 to 6, a low value represents a better outcome.","timeFrame":"90 days"}],"secondaryOutcomes":[{"measure":"National Institute of Health Stroke Scale (NIHSS) at 7days.","description":"National Institute of Health stroke Scale (NIHSS) ranged from 0 to 42, a low value represents a better outcome.","timeFrame":"7days"},{"measure":"Incidence of ischemic stroke within 90 days.","description":"Including recurrent and new ischemic stroke.","timeFrame":"0-90days"},{"measure":"Adverse events occurring in the course of the treatment.","description":"Including all adverse events, severe adverse events and urinary kallidinogenase related adverse events.","timeFrame":"0-7days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age ≥18 years old;\n2. Acute anterior circulation large artery atherosclerotic cerebral infarction (according to TOAST classification) within 48h of onset; NIHSS score ≥6, ≤15;\n3. Moderate to severe stenosis or occlusion of offending vessels;\n4. The mRS Score ≤2 before onset;\n5. Subjects or their legal representatives agreed to the treatment and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Transient ischemic attack;\n2. Patients who planned or had received emergency reperfusion therapy (including intravenous thrombolysis and emergency thrombectomy);\n3. Severe disturbance of consciousness:GCS ≤8;\n4. Patients who previously received angiotensin-converting enzyme inhibitor (ACEI) drugs regularly;\n5. Refractory hypertension: systolic blood pressure ≥200 mmHg or diastolic blood pressure ≥110 mmHg; hypotension: systolic blood pressure \\< 90 mmHg or diastolic blood pressure \\< 60 mmHg;\n6. Liver dysfunction (ALT/AST \\>1.5 × upper limit of normal \\[ULN\\]), renal dysfunction (Cr \\>1 × ULN);\n7. Coagulopathy (prolonged INR (\\>1.5) or prolonged APTT (\\>2 folds);\n8. Cardioembolic stroke or high-risk factors of cardioembolic stroke identified by investigators (atrial fibrillation, cardiac mural thrombus, cardiomyopathy, etc.);\n9. Special populations such as pregnant and lactating women, patients with life expectancy less than 3 months, or patients unable to complete the study for other reasons;\n10. Unwilling to be followed up or poor treatment compliance;\n11. Participating in other clinical investigators, or had participated in other clinical investigators within 3 months before enrollment;\n12. Other conditions considered by the investigator to be inappropriate for enrollment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Yi Yang, MD,PhD","role":"CONTACT","phone":"13756661217","phoneExt":"0086","email":"doctoryangyi@163.com"},{"name":"Zhenni Guo, MD,PhD","role":"CONTACT","phone":"18186872986","phoneExt":"0086","email":"zhen1ni2@163.com"}],"overallOfficials":[{"name":"Yi Yang, MD,PhD","affiliation":"The First Hospital of Jilin University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"First Hospital of Jilin University","city":"Changchun","state":"Jilin","zip":"130000","country":"China","contacts":[{"name":"Yi Yang, MD,PhD","role":"CONTACT","phone":"13756661217","phoneExt":"0086","email":"doctoryangyi@163.com"},{"name":"Zhenni Guo, MD,PhD","role":"CONTACT","phone":"18186872986","phoneExt":"0086","email":"zhen1ni2@163.com"}],"geoPoint":{"lat":43.88,"lon":125.32278}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000050197","term":"Atherosclerosis"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"},{"id":"D000001161","term":"Arteriosclerosis"},{"id":"D000001157","term":"Arterial Occlusive Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M25878","name":"Atherosclerosis","asFound":"Atherosclerosis","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M4159","name":"Arteriosclerosis","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000007610","term":"Kallikreins"}],"ancestors":[{"id":"D000003029","term":"Coagulants"},{"id":"D000005303","term":"Fertility Agents, Male"},{"id":"D000005299","term":"Fertility Agents"},{"id":"D000012102","term":"Reproductive Control Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M10328","name":"Kallikreins","asFound":"eNOS","relevance":"HIGH"},{"id":"M5949","name":"Coagulants","relevance":"LOW"}],"browseBranches":[{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"Repr","name":"Reproductive Control Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}